Skip to content
Company Analysis

Gelteq Limited GELS

A comprehensive view of key metrics, scores, and financial health for Gelteq Limited

Overview of Gelteq Limited

GELS NCM
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Micro Cap
Gelteq Limited (GELS), is a Micro Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $0.99, about 0.0% overvalued vs fair value, -52.9% 1Y return, ranked 922/1122 in sector.
Metrics ROE -43.0%
USD 0.99
-35.29%
(Delayed)
• Vol 90d: 215.4%
52-Week Range
Market Cap
$5.51M
Enterprise Value
$9.38M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Fair
Valuation
Weak
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Fair
Valuation
Weak
Completeness: 70%
Confidence: 45%
Updated: Mar 8
Top Beats
No strong beats yet

Quick Facts

Website https://www.gelteq.com
HQ Clayton, VIC
Employees 7
Fiscal year Jun 30

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$-1
$-1
$-1
Current: $0.99

Engine Room Money Flow™

Micro Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$165.6K
Gross Profit
$165.6K
R&D Expense
$628.6K
127.7%%
Operating Income (EBIT)
$-4.8M
-60.4%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

R&D Intensity
379.5%
Fair

High R&D intensity - heavy pipeline investment

Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
Analysis based on partial data. Some metrics unavailable for complete assessment.
2
Active Leaks
1/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Gelteq Limited's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
17
/100
Weak
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
11
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 88% Coverage
Trade-Off Triangle Visualization A ternary plot showing GELS's balance between Growth (38.7%), Profitability (21.0%), and Safety (40.3%). Growth 39% Safety 40% Profitability 21%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

25th percentile vs peers
25
Key Signals
Revenue CAGR 3Y 3.9% 44p EPS Growth YoY -1.1% 35p Rev Growth YoY -1.00 2p
Strengths

No notable strengths identified for this axis.

Risks
  • Rev Growth YoY in bottom 20% of peers (-1.00)

Profitability

13th percentile vs peers
14
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

26th percentile vs peers
26
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Gelteq Limited.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-0.66
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000